Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription 23.02.2026 1 Am J Gastroenterol 2 Biochem Biophys Res Commun 2 BMC Cancer 2 BMC Gastroenterol 1 Dig Dis Sci 3 Endoscopy 1 Eur Radiol 1 Gastrointest Endosc 1 Gut 7 Hepatology 1 Int J Cancer 1 J Gastroenterol Hepatol 9 J Hepatol 1 N Engl J Med 2 PLoS One 2 Proc Natl Acad Sci U S A 2 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. OCHOA-ALLEMANT P, Kiran A, Mezzacappa C, Kaplan DE, et al
   Steatotic Liver Disease Has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the U.S. Veterans Health System.
   Am J Gastroenterol. 2026 Feb 18. doi: 10.14309/ajg.0000000000003966.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. XU J, Yang H, Wei H, Li H, et al
   Atractylon induces autophagy-dependent apoptosis in hepatocellular carcinoma cells via inhibition of the PI3K/AKT/mTOR pathway.
   Biochem Biophys Res Commun. 2026;808:153465.
   PubMed         Abstract available
   
   
3. FUJIWARA N, Mitsui I, Tsunedomi R, Hayakawa K, et al
   Protein phosphatase 6 protects hepatocytes from endoplasmic reticulum and oxidative stress by suppressing Akt/mTOR signaling.
   Biochem Biophys Res Commun. 2026;808:153463.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. LIU X, Wang Z, Lv X, Wang J, et al
   Immune effect of Traditional Chinese Medicine combined with transcatheter arterial chemoembolization in treatment of liver cancer: a meta-analysis.
   BMC Cancer. 2026;26:263.
   PubMed         Abstract available
   
   
5. YANG Z, Li T, Shen J, Huang Y, et al
   Multi-omics SMR and experimental supportive analyses decipher causal drivers hepatocellular carcinoma.
   BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15667.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

6. ZHONG HY, Ma LD, Li JC, Jiang D, et al
   Associations of relative fat mass with metabolic dysfunction-associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017-2023.
   BMC Gastroenterol. 2026;26:139.
   PubMed         Abstract available
   
   
7. LIU Y, Zhang Q, Li J, Wu X, et al
   mNGS improves the efficiency of infection diagnosis and treatment in acute-on-chronic liver failure.
   BMC Gastroenterol. 2026;26:129.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

8. ZHANG Q, Liu P, Xu X, Yang Y, et al
   Clinical Outcomes of Acute Pancreatitis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis.
   Dig Dis Sci. 2025 Aug 14. doi: 10.1007/s10620-025-09300.
   PubMed         Abstract available
   
   

   
   Endoscopy

9. NAMIMA D, Kamada H, Shimizu Y, Fujita N, et al
   Handmade snare technique for grasping and repositioning biliary stents via the endoscopic ultrasound-guided hepaticojejunostomy route.
   Endoscopy. 2026;58.
   PubMed        
   
   
10. HARA A, Minaga K, Otsuka Y, Takenaka M, et al
    Rescue multihole metal stent placement to prevent stent migration after endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026;58.
    PubMed        
    
    
11. MARUYAMA H, Ishikawa-Kakiya Y, Kawata Y, Kurokawa T, et al
    Troubleshooting: intraperitoneal migration of a dedicated plastic stent during endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026;58.
    PubMed        
    
    

    
    Eur Radiol

12. ZHOU J, Ouyang S, Chen H, Zhang D, et al
    The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma
    Eur Radiol. 2026 Feb 20. doi: 10.1007/s00330-026-12381.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

13. RANA SS, Mewara A, Acharya R, Reddysetti S, et al
    Cholangioscopic Diagnosis of Intrahepatic Fascioliasis Presenting as Eosinophilic Ascites in a Non-Endemic Area.
    Gastrointest Endosc. 2026 Feb 17:S0016-5107(26)00116.
    PubMed        
    
    

    
    Gut

14. BHANUSHALI M, Bhagat N, De A, Duseja A, et al
    Metabolic determinants of hepatocellular carcinoma after SVR: persisting uncertainties.
    Gut. 2026 Feb 20:gutjnl-2026-338377. doi: 10.1136/gutjnl-2026-338377.
    PubMed        
    
    

    
    Hepatology

15. MA X, Niu M, Ni HM, Ding WX, et al
    Mitochondrial dynamics, quality control, and mtDNA in alcohol-associated liver disease and liver cancer.
    Hepatology. 2026;83:639-660.
    PubMed         Abstract available
    
    
16. QI X, Li J, Caussy C, Teng GJ, et al
    Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:661-678.
    PubMed         Abstract available
    
    
17. GOLDBERG D, Blandon C, Delgado C, John B, et al
    Simulating the impact of survival benefit-based liver transplant organ allocation.
    Hepatology. 2025 Apr 4. doi: 10.1097/HEP.0000000000001338.
    PubMed         Abstract available
    
    
18. SCHWIMMER JB, Thai NQN, Noon SL, Ugalde-Nicalo P, et al
    Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study.
    Hepatology. 2026;83:561-574.
    PubMed         Abstract available
    
    
19. PIROLA CJ, Diambra L, Fernandez Gianotti T, Castano GO, et al
    Organ damage proteomic signature identifies patients with MASLD at risk of systemic complications.
    Hepatology. 2026;83:623-638.
    PubMed         Abstract available
    
    
20. VAN KLEEF LA, Pustjens J, Schattenberg JM, Holleboom AG, et al
    Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.
    Hepatology. 2026;83:591-602.
    PubMed         Abstract available
    
    
21. ZHANG D, Abulitipu A, Pang P, Bai L, et al
    ECM1 protects against liver steatosis through PCBP1-mediated iron homeostasis.
    Hepatology. 2026;83:603-622.
    PubMed         Abstract available
    
    

    
    Int J Cancer

22. SCOTT KJ, West EJ, Brownlie RJ, Ismail F, et al
    Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.
    Int J Cancer. 2026 Feb 16. doi: 10.1002/ijc.70386.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

23. JIANG E, Chen Y, Chen M, Zhou Y, et al
    Oncogenic LPCAT1 Accelerates Intrahepatic Cholangiocarcinoma Development Through PI3K/Akt Signaling-Dependent Cell Cycle Regulation.
    J Gastroenterol Hepatol. 2026 Feb 19. doi: 10.1111/jgh.70291.
    PubMed         Abstract available
    
    

    
    J Hepatol

24. SU JY, Lin LP, Huang ZH, Pan LX, et al
    Adjuvant Immunotherapy for Hepatocellular Carcinoma: Precision Selection of the Optimal Beneficiary Population as the Core Strategy.
    J Hepatol. 2026 Feb 15:S0168-8278(26)00075-9. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
25. CAI J, Yip TC, Wong GL, Zhang Y, et al
    Global epidemiology of bacterial infections in patients with cirrhosis: a systematic review and meta-analysis.
    J Hepatol. 2026 Feb 16:S0168-8278(26)00071-1. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
26. TELLEZ L, Donate J, Albillos A
    Early portopulmonary hypertension: a signal of increased mortality risk in cirrhosis.
    J Hepatol. 2026 Feb 17:S0168-8278(26)00074-7. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
27. XU C, Sun J, Liang Q, Zhao H, et al
    Conversion surgery as a missing outcome in first-line immunotherapy trials for hepatocellular carcinoma: Conversion surgery in HCC immunotherapy.
    J Hepatol. 2026 Feb 18:S0168-8278(26)00025-5. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
28. VILAR-GOMEZ E, Yates KP, Kleiner DE, Behling C, et al
    Genetic and non-genetic drivers of histological progression and regression in MASLD.
    J Hepatol. 2026;84:502-516.
    PubMed         Abstract available
    
    
29. EL-SERAG HB, Lopez C, Luster M, Reddy KR, et al
    HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.
    J Hepatol. 2026;84:578-586.
    PubMed         Abstract available
    
    
30. ZHANG W, Xu Q, Xu K, Jiang R, et al
    Genetically engineered pig-to-human liver xenotransplantation.
    J Hepatol. 2026;84:587-598.
    PubMed         Abstract available
    
    
31. REIG M, Sanduzzi-Zamparelli M, Forner A, Rimola J, et al
    BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.
    J Hepatol. 2026;84:631-654.
    PubMed         Abstract available
    
    
32. JIA XZ, Zhuang TT, Yang RS, Gu YW, et al
    Setd4-expressing cells drive regenerative recovery in chronic liver injury.
    J Hepatol. 2026;84:554-566.
    PubMed         Abstract available
    
    

    
    N Engl J Med

33. MUMOLI N, Serio G
    Hepatic Angiosarcoma.
    N Engl J Med. 2026;394:e11.
    PubMed        
    
    

    
    PLoS One

34. TANVIR L, Afzal K, Abbas A, Amjad A, et al
    Integrating phytochemical analysis and experimental validation of Ziziphus jujuba seed powder and oil to ameliorate CCl4-induced liver fibrosis in sprague dawley rats.
    PLoS One. 2026;21:e0343428.
    PubMed         Abstract available
    
    
35. CHEN Z, Fan Y, Luo Y, Ye X, et al
    Hepatic arterial infusion chemotherapy (HAlC) versus sorafenib for hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) B/C: A systematic review and meta-analysis.
    PLoS One. 2026;21:e0342495.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

36. QIN XY, Xu Y, Mishra H, Shirakami Y, et al
    Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.
    Proc Natl Acad Sci U S A. 2026;123:e2521923123.
    PubMed         Abstract available
    
    
37. HANNA BS, Langston PK, Marin-Rodero M, Ramirez RN, et al
    Regulatory T cells safeguard liver health during metabolic-associated steatohepatitis.
    Proc Natl Acad Sci U S A. 2026;123:e2536314123.
    PubMed         Abstract available
    
    

    
    Transplantation

38. HILL A, Hu Y, Park Y, Lovasik B, et al
    Low Model for End-Stage Liver Disease Score Patients Experience Significant Survival Advantage With Liver Transplantation.
    Transplantation. 2026 Jan 5. doi: 10.1097/TP.0000000000005601.
    PubMed         Abstract available
    
    
39. DONNELLY C, Kim JI, Motter JD, Ishaque T, et al
    Temporal Changes in Access to Transplantation Among Pediatric Registrants.
    Transplantation. 2026;110:e637-e646.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum